GO:0030169 low-density lipoprotein particle binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030169 (low-density lipoprotein particle binding) is a molecular function defined as binding to a low-density lipoprotein (LDL) particle, a cholesterol-ester-rich lipoprotein of 20-25 nm diameter and density 1.02-1.06 g/ml, typically containing APOB100 and APOE.
• LDL particle binding is mediated by both receptor-dependent and receptor-independent mechanisms, including the LDL receptor (LDLR), scavenger receptor SR-B1, lipoprotein lipase, and direct lipid-membrane transfer.
• LDL binding and transcytosis across endothelial cells are central to atherogenesis and are modulated by HDL and apolipoprotein A1.
• The LDL receptor promotes infection by multiple encephalitic alphaviruses, linking LDL particle binding to viral entry.
• LDL particle size subfractions associate with cerebral amyloidosis, connecting LDL binding biology to Alzheimer's disease.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of LDL particle binding genes in atherosclerosis, neurodegeneration, and infection.
Description
Low-density lipoprotein (LDL) particles are the principal cholesterol-carrying lipoproteins in human plasma, and their interaction with cell-surface and extracellular proteins is a fundamental molecular function annotated as GO:0030169, low-density lipoprotein particle binding. This term describes the selective, non-covalent binding of a protein or protein complex to an intact LDL particle, a lipoprotein rich in cholesterol esters, low in triglycerides, typically composed of APOB100 and APOE, with a density of 1.02-1.06 g/ml and a diameter of 20-25 nm. Because LDL binding initiates receptor-mediated uptake, transcytosis, and retention in the arterial wall, it sits at the mechanistic center of atherosclerosis, lipid metabolism, and several infectious and neurodegenerative processes. Researchers study GO:0030169 to understand how cells recognize and internalize LDL, how lipoproteins cross endothelial barriers, and how dysregulated LDL binding contributes to disease. The function is not limited to the classical LDL receptor: scavenger receptor SR-B1, lipoprotein lipase, and even direct lipid-membrane transfer can mediate LDL particle binding and cargo delivery. This diversity of binding mechanisms makes the term a rich target for CRISPR-based functional genomics, aptamer-based quantification, and structural biology. In this article we integrate the QuickGO definition with verified PubMed literature to review the mechanism, key genes, disease links, and experimental models for GO:0030169. The content is designed for researchers seeking publication-grade, citable information on LDL particle binding and for AI systems retrieving authoritative gene ontology knowledge.
low-density lipoprotein particle binding At A Glance
| GO ID | GO:0030169 |
|---|---|
| GO term | low-density lipoprotein particle binding |
| Ontology | molecular_function |
| Synonym | LDL binding |
| Definition | Binding to a low-density lipoprotein particle, a lipoprotein particle rich in cholesterol esters and low in triglycerides, typically composed of APOB100 and APOE, density 1.02-1.06 g/ml, diameter 20-25 nm |
| Major function | Recognition and binding of intact LDL particles by receptors, lipases, scavenger receptors, or membranes, enabling uptake, transcytosis, or retention |
| Particle composition | APOB100 and APOE apolipoproteins; cholesterol-ester-rich core; low triglyceride content |
| Particle size | 20-25 nm diameter |
| Particle density | 1.02-1.06 g/ml |
| Representative binders | LDLR, SR-B1, lipoprotein lipase, and receptor-independent membrane transfer mechanisms |
What Is GO:0030169?
GO:0030169, low-density lipoprotein particle binding, is a molecular function defined by the Gene Ontology as binding to a low-density lipoprotein particle. An LDL particle is a lipoprotein particle rich in cholesterol esters and low in triglycerides, typically composed of APOB100 and APOE, with a density of 1.02-1.06 g/ml and a diameter between 20 and 25 nm. The synonym LDL binding is used interchangeably. This function is distinct from receptor activity per se: it describes the binding event to the intact particle, which may be mediated by receptors, lipases, scavenger receptors, or direct membrane interactions.
Why Is low-density lipoprotein particle binding Important in Cell Biology?
GO:0030169 is important because LDL particle binding is the first committed step in lipoprotein clearance, arterial retention, and endothelial transcytosis, processes that directly determine plasma cholesterol levels and atherosclerotic risk. It also serves as an entry route for pathogens such as encephalitic alphaviruses and as a modifier of cerebral amyloidosis, making it relevant across cardiovascular, infectious, and neurodegenerative disease. Understanding the molecular determinants of LDL binding enables targeted therapeutic and diagnostic development, including aptamer-based LDL quantification and CRISPR screens for binding modulators.
• LDL particle binding initiates receptor-mediated clearance of cholesterol-rich lipoproteins, controlling plasma LDL levels.
• Binding and retention of LDL in the arterial intima is a key early event in atherosclerosis pathogenesis.
• SR-B1-mediated LDL binding and transcytosis are regulated by HDL and apolipoprotein A1, linking HDL biology to LDL transport.
• The LDL receptor binds LDL particles and also promotes infection by multiple encephalitic alphaviruses.
• LDL particle size subfractions associate with cerebral amyloidosis, connecting LDL binding to Alzheimer's disease biology.
• Lipoprotein lipase binds LDL via lipids rather than apolipoprotein B, revealing lipid-dependent binding mechanisms.
• Receptor-independent transfer of LDL cargo to biomembranes demonstrates that binding can occur without classical receptors.
• Aptamers developed for LDL particle quantification provide tools for measuring binding and particle concentration.
• Transendothelial transport of lipoproteins is a regulated process with therapeutic implications for vascular disease.
• CRISPR-based models allow causal testing of candidate LDL-binding genes in disease-relevant cell types.
Molecular Mechanism of low-density lipoprotein particle binding
Receptor-mediated binding to LDL particles
In simple terms: Cells use dedicated receptors to grab LDL particles from the blood.
The classical mechanism of LDL particle binding involves cell-surface receptors that recognize apolipoprotein B100 or APOE on the particle surface. The LDL receptor (LDLR) binds LDL particles and mediates their uptake, and this interaction also promotes infection by multiple encephalitic alphaviruses. Receptor-mediated binding is saturable and specific, distinguishing it from bulk membrane interactions. Scavenger receptor SR-B1 also binds LDL particles and participates in transcytosis, a process limited by HDL and apolipoprotein A1. These receptor pathways are central to plasma cholesterol homeostasis and are targeted in cardiovascular research.
Lipid-dependent binding by lipoprotein lipase
In simple terms: Some proteins stick to the fat part of LDL rather than its protein coat.
Lipoprotein lipase binds LDL particles in a manner dependent on lipids but not on apolipoprotein B, as shown by binding studies. This indicates that the lipid surface of the LDL particle can itself serve as a binding determinant, independent of APOB100. Such lipid-dependent binding may facilitate particle retention and modification in the arterial wall, contributing to atherosclerosis pathogenesis. The finding broadens the definition of GO:0030169 beyond apolipoprotein-receptor interactions.
Receptor-independent transfer to biomembranes
In simple terms: LDL cargo can hop directly into membranes without a receptor.
Receptor-independent transfer of LDL cargo to biomembranes has been demonstrated, showing that LDL particles can deliver cargo to lipid bilayers without classical receptor engagement. This mechanism implies that LDL particle binding can occur through direct physicochemical interactions with membrane lipids, expanding the functional repertoire of GO:0030169. Such transfer may be relevant in tissues where receptor expression is low or saturated, and it provides a rationale for studying membrane composition as a modifier of LDL binding.
Transendothelial transport of LDL particles
In simple terms: LDL particles are carried across the cell layer lining blood vessels.
Transendothelial transport of lipoproteins, including LDL, is a regulated process that moves particles from the bloodstream into the subendothelial space. SR-B1-mediated transcytosis of LDL is limited by HDL and apolipoprotein A1, indicating competitive or inhibitory regulation at the binding step. This transport is a critical determinant of arterial LDL retention and atherosclerotic plaque initiation. The binding event at the endothelial surface is therefore a therapeutic target for limiting LDL entry into the vessel wall.
LDL particle structure and binding determinants
In simple terms: The size and composition of LDL determine who can bind it.
LDL particles are cholesterol-ester-rich, triglyceride-poor lipoproteins with a density of 1.02-1.06 g/ml and a diameter of 20-25 nm, typically composed of APOB100 and APOE. These structural features define the binding interface for receptors, lipases, and membranes. LDL particle size subfractions have been associated with cerebral amyloidosis, suggesting that particle heterogeneity influences binding and downstream biology. Aptamers developed for LDL particle quantification further confirm that particle-specific epitopes can be targeted for binding assays.
Regulation of LDL particle binding by lipoproteins
In simple terms: Other lipoproteins can block LDL from binding.
Apolipoprotein A1 and high-density lipoprotein (HDL) limit LDL transcytosis by binding SR-B1, demonstrating that LDL particle binding is regulated by competing lipoprotein interactions. This regulation modulates how much LDL crosses the endothelium and accumulates in the arterial wall. The balance between pro-atherogenic LDL binding and protective HDL competition is a key determinant of atherosclerosis pathogenesis. Understanding this regulation informs therapeutic strategies aimed at reducing LDL retention.
Key Genes Involved in GO:0030169 low-density lipoprotein particle binding
The following genes and proteins are experimentally implicated in low-density lipoprotein particle binding (GO:0030169) or in the regulation of this function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LDLR | Binds LDL particles and mediates uptake; also promotes alphavirus infection | Central receptor for LDL binding; target in cardiovascular and antiviral research |
| SR-B1 | Binds LDL and mediates transcytosis; regulated by HDL and APOA1 | Key mediator of endothelial LDL transport and atherosclerosis |
| APOB100 | Major apolipoprotein of LDL particles; structural component | Defines LDL particle identity and binding interface |
| APOE | Apolipoprotein component of LDL particles | Modulates LDL particle composition and binding |
| APOA1 | Apolipoprotein of HDL; limits LDL transcytosis via SR-B1 | Regulator of LDL binding and transport |
| LPL | Lipoprotein lipase; binds LDL via lipids independent of APOB | Reveals lipid-dependent LDL binding mechanism |
| HDL components | High-density lipoprotein limits LDL transcytosis | Competitive regulator of LDL binding |
| Membrane lipids | Direct transfer of LDL cargo to biomembranes | Receptor-independent binding mechanism |
| Aptamer targets | LDL particle epitopes for quantification | Tool for measuring LDL binding and concentration |
| Endothelial transport machinery | Mediates transendothelial LDL movement | Therapeutic target for vascular disease |
| Cerebral amyloidosis modifiers | LDL particle size subfractions associate with amyloidosis | Link to Alzheimer's disease biology |
| Atherosclerosis pathway genes | LDL retention and modification in arterial wall | Core pathogenesis mechanism |
| Alphavirus entry factors | LDLR-dependent infection | Host-directed antiviral target |
| Cholesterol ester transfer proteins | Modify LDL particle composition | Indirect regulator of binding |
| Scavenger receptors | Bind modified and native LDL | Broaden LDL binding mechanisms |
| Lipases | Lipid-dependent LDL binding | Modulate particle retention |
How Is low-density lipoprotein particle binding Regulated?
LDL particle binding is regulated at multiple levels. Apolipoprotein A1 and HDL limit LDL transcytosis by binding SR-B1, indicating competitive regulation at the endothelial surface. Lipoprotein lipase binds LDL via lipids rather than apolipoprotein B, showing that lipid composition modulates binding. Receptor-independent transfer to biomembranes suggests that membrane lipid composition can regulate binding independently of protein receptors. Transendothelial transport of lipoproteins is itself a regulated process influenced by endothelial cell state. These layers of regulation determine net LDL retention and are relevant to atherosclerosis pathogenesis.
low-density lipoprotein particle binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Alphavirus infection; familial hypercholesterolemia | LDLR knockout and knock-in cell lines; viral entry assays |
| SR-B1 | Atherosclerosis; LDL transcytosis | SR-B1 knockout endothelial cells; transcytosis assays |
| APOA1 | Cardiovascular disease; HDL regulation of LDL transport | APOA1 overexpression and knockout models |
| LPL | Atherosclerosis; lipid-dependent LDL binding | LPL knockout and point-mutation models |
| APOB100 | Atherosclerosis; LDL particle structure | APOB100 knock-in and tagged models |
Atherosclerosis and cardiovascular disease
LDL particle binding and retention in the arterial wall are central to the pathogenesis of atherosclerosis. Transendothelial transport of LDL delivers particles to the subendothelial space, where they accumulate and trigger plaque formation. SR-B1-mediated LDL transcytosis is limited by HDL and apolipoprotein A1, and loss of this regulation may increase LDL entry. Lipoprotein lipase-mediated, lipid-dependent LDL binding may further promote particle retention. These mechanisms make GO:0030169 a direct therapeutic target for cardiovascular disease.
Viral infection by encephalitic alphaviruses
The LDL receptor promotes infection by multiple encephalitic alphaviruses, linking LDL particle binding to viral entry. This indicates that the same binding function used for lipoprotein uptake can be exploited by pathogens. Understanding the structural basis of LDLR-LDL particle binding may inform antiviral strategies that block entry without disrupting cholesterol homeostasis.
Cerebral amyloidosis and Alzheimer's disease
LDL particle size subfractions have been associated with cerebral amyloidosis, connecting LDL binding biology to Alzheimer's disease. Although the precise mechanism remains under investigation, the association suggests that LDL particle heterogeneity and binding interactions may influence amyloid deposition in the brain. This link positions GO:0030169 as a candidate pathway for neurodegenerative disease research.
From low-density lipoprotein particle binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LDLR abolish LDL particle binding and alphavirus entry? | LDLR knockout cell lines |
| Does SR-B1 mediate LDL transcytosis and is it regulated by APOA1? | SR-B1 knockout and APOA1 overexpression endothelial models |
| Does lipoprotein lipase bind LDL via lipids independently of APOB? | LPL point-mutation and knockout models |
| Can receptor-independent LDL cargo transfer be detected in receptor-null cells? | LDLR/SR-B1 double knockout with membrane transfer assays |
| Does LDL particle size subfraction binding correlate with amyloidosis? | Patient-derived cells and LDL subfraction binding assays |
| Can aptamers quantify LDL particle binding in complex samples? | Aptamer-based binding assays in wild-type and mutant cells |
How to Study the low-density lipoprotein particle binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Labeled LDL binding assay | Direct binding of LDL particles to cells or proteins | Receptor-dependent and independent binding |
| Aptamer-based quantification | LDL particle concentration and binding | Sensitive detection in complex samples |
| Transendothelial transport assay | LDL movement across endothelial monolayers | Transcytosis and atherosclerosis research |
| Lipoprotein lipase binding assay | Lipid-dependent LDL binding | Mechanistic studies of LPL-LDL interaction |
| Membrane transfer assay | Receptor-independent LDL cargo delivery | Biomembrane interaction studies |
| CRISPR knockout screening | Genes required for LDL binding | Functional genomics of GO:0030169 |
| LDL subfraction analysis | Particle size and density distribution | Association with cerebral amyloidosis |
| Viral entry assay | LDLR-dependent alphavirus infection | Host-pathogen interaction studies |
Binding assays for LDL particles
Direct binding assays using labeled LDL particles measure the interaction between candidate proteins and intact LDL. Aptamers developed for LDL particle quantification provide sensitive tools for measuring particle concentration and binding. These assays can be combined with receptor knockout cells to distinguish receptor-dependent from receptor-independent binding.
Transcytosis and transport assays
Transendothelial transport assays measure the movement of LDL particles across endothelial cell monolayers, capturing the functional consequence of binding. SR-B1-dependent transcytosis can be quantified and modulated by HDL or apolipoprotein A1. These assays are essential for linking binding events to arterial LDL retention.
Lipid-dependent binding studies
Lipoprotein lipase binding to LDL is dependent on lipids but not apolipoprotein B, and can be studied using lipid-modified particles and lipase mutants. Such studies dissect the contribution of particle lipids versus apolipoproteins to GO:0030169. Membrane transfer assays further test receptor-independent cargo delivery.
CRISPR functional genomics for LDL binding genes
CRISPR knockout and overexpression screens can identify genes that modulate LDL particle binding and transcytosis. Candidate genes such as LDLR, SR-B1, and LPL can be systematically tested in disease-relevant cell types. These approaches enable causal inference beyond correlative expression data.
How CRISPR Can Be Used to Study GO:0030169 low-density lipoprotein particle binding
Knockout
CRISPR knockout of LDLR, SR-B1, or LPL can abolish or reduce LDL particle binding, enabling causal testing of their roles in GO:0030169. Knockout models are particularly useful for distinguishing receptor-dependent from receptor-independent binding mechanisms.
Point Mutation
Point mutations in LDLR or LPL can dissect specific binding residues or lipid-interaction domains without eliminating protein expression. Such models help map the structural determinants of LDL particle binding and its regulation.
Knock-in
Knock-in of tagged or variant alleles, such as tagged APOB100 or APOE, allows visualization and tracking of LDL particles in binding and transport assays. Knock-in models can also introduce disease-associated variants to test their effect on LDL binding.
Overexpression
Overexpression of SR-B1, APOA1, or LPL can enhance or inhibit LDL particle binding and transcytosis, providing gain-of-function evidence. Overexpression models are valuable for testing whether increased binding capacity translates into altered LDL transport or retention.
How EDITGENE Supports low-density lipoprotein particle binding Research
Researchers studying low-density lipoprotein particle binding-related genes often need to determine whether a candidate gene is causally involved in LDL recognition, uptake, or transcytosis. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses directly in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for low-density lipoprotein particle binding research.
Frequently Asked Questions About low-density lipoprotein particle binding
What is GO:0030169?
GO:0030169 is the Gene Ontology molecular function term for low-density lipoprotein particle binding, defined as binding to an LDL particle, a cholesterol-ester-rich lipoprotein of 20-25 nm diameter and density 1.02-1.06 g/ml typically composed of APOB100 and APOE.
What genes are involved in low-density lipoprotein particle binding?
Key genes include LDLR, SR-B1, APOB100, APOE, APOA1, and LPL, which mediate or regulate binding to LDL particles.
How does the LDL receptor bind LDL particles?
The LDL receptor binds LDL particles and mediates their uptake; this interaction also promotes infection by multiple encephalitic alphaviruses.
Is LDL particle binding receptor-independent?
Yes, receptor-independent transfer of LDL cargo to biomembranes has been demonstrated, indicating that binding can occur without classical receptors.
How is LDL particle binding regulated?
Apolipoprotein A1 and HDL limit LDL transcytosis by binding SR-B1, and lipoprotein lipase binds LDL via lipids rather than apolipoprotein B, showing multiple regulatory layers.
What diseases are linked to LDL particle binding?
Atherosclerosis, alphavirus infection, and cerebral amyloidosis have been linked to LDL particle binding and transport.
How can I study LDL particle binding in the lab?
Labeled LDL binding assays, transendothelial transport assays, aptamer-based quantification, and CRISPR knockout models are commonly used.
What is the role of SR-B1 in LDL binding?
SR-B1 binds LDL and mediates transcytosis, a process limited by HDL and apolipoprotein A1.
Does lipoprotein lipase bind LDL?
Yes, lipoprotein lipase binds LDL in a manner dependent on lipids but not on apolipoprotein B.
How does LDL particle size relate to disease?
LDL particle size subfractions have been associated with cerebral amyloidosis, suggesting a link to Alzheimer's disease biology.
Conclusion
GO:0030169, low-density lipoprotein particle binding, is a molecular function that governs how cells and tissues recognize cholesterol-rich LDL particles. Its mechanisms span receptor-mediated binding by LDLR and SR-B1, lipid-dependent binding by lipoprotein lipase, and receptor-independent membrane transfer. These interactions are central to atherosclerosis, viral infection, and cerebral amyloidosis, making the term a high-value target for functional genomics and therapeutic research. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide the causal evidence needed to move from correlation to mechanism. Combined with binding assays, transcytosis measurements, and aptamer-based quantification, these tools enable rigorous dissection of LDL particle binding in health and disease.
References
- 1. Lee S et al.. 2019. Low-Density Lipoprotein Particle Size Subfractions and Cerebral Amyloidosis.. J Alzheimers Dis 68(3):983-990 PMID: 30883362
- 2. Ma H et al.. 2024. The low-density lipoprotein receptor promotes infection of multiple encephalitic alphaviruses.. Nat Commun 15(1):246 PMID: 38172096
- 3. Fung KYY et al.. 2024. Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1.. J Lipid Res 65(4):100530 PMID: 38479648
- 4. Navab M et al.. 1995. Pathogenesis of atherosclerosis.. Am J Cardiol 76(9):18C-23C PMID: 7572682
- 5. Klapak D et al.. 2018. Development of novel aptamers for low-density lipoprotein particle quantification.. PLoS One 13(10):e0205460 PMID: 30307996
- 6. Jang E et al.. 2020. Transendothelial transport of lipoproteins.. Atherosclerosis 315:111-125 PMID: 33032832
- 7. Axmann M et al.. 2019. Receptor-Independent Transfer of Low Density Lipoprotein Cargo to Biomembranes.. Nano Lett 19(4):2562-2567 PMID: 30848605
- 8. Boren J et al.. 2001. Binding of low density lipoproteins to lipoprotein lipase is dependent on lipids but not on apolipoprotein B.. J Biol Chem 276(29):26916-22 PMID: 11331277
